1,106 results match your criteria: "Canada (J.W.); and the Thrombosis and Atherosclerosis Research Institute[Affiliation]"
N Engl J Med
January 2025
From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston (C.T.R., S.M.P., R.P.G., D.A.M., J.F.K., E.L.G., S.A.M., S.D.W., M.S.S.); Anthos Therapeutics, Cambridge, MA (B.H., S.P., D.B.); the Heart Rhythm Center, Taipei Veterans General Hospital and Cardiovascular Center, Taipei, Taiwan (S.-A.C.); Taichung Veterans Hospital, Taichung, Taiwan (S.-A.C.); National Yang Ming Chiao Tung University, Hsinchu, Taiwan (S.-A.C.); National Chung Hsing University, Taichung, Taiwan (S.-A.C.); St. Michael's Hospital, Unity Health Toronto, Peter Munk Cardiac Centre, University Health Network, University of Toronto, Toronto (S.G.G.); Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (S.G.G.); the Division of Cardiology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea (B.J.); the Department of Cardiology, Central Hospital of Northern Pest-Military Hospital, Budapest, Hungary (R.G.K.); the Heart and Vascular Center, Semmelweis University, Budapest, Hungary (R.G.K.); the Internal Cardiology Department, St. Ann University Hospital and Masaryk University, Brno, Czech Republic (J.S.); the Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland (W.W.); the Departments of Medicine and of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada (J.W.); and the Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada (J.W.).
Background: Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in patients with atrial fibrillation is unknown.
Methods: Patients with atrial fibrillation and a moderate-to-high risk of stroke were randomly assigned, in a 1:1:1 ratio, to receive subcutaneous injection of abelacimab (150 mg or 90 mg once monthly) administered in a blinded fashion or oral rivaroxaban (20 mg once daily) administered in an open-label fashion.
CNS Drugs
January 2025
Innovative Medicines and Global Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Background: Huntington disease (HD) is a progressive neurodegenerative disease that causes psychiatric and neurological symptoms, including involuntary and irregular muscle movements (chorea). Chorea can disrupt activities of daily living, pose safety issues, and may lead to social withdrawal. The vesicular monoamine transporter 2 inhibitors tetrabenazine, deutetrabenazine, and valbenazine are approved treatments that can reduce chorea.
View Article and Find Full Text PDFStroke
January 2025
Population Health Research Institute, University of British Columbia, Vancouver, Canada. (M.A.S., J.W.E., A.H.K., A. Shoamanesh, A.T., R.G.H., A.C., R.Z.).
Background: Stroke secondary to intracranial atherosclerotic disease (ICAD) is associated with high recurrence risk despite currently available secondary prevention strategies. In patients with systemic atherosclerosis, a significant reduction of stroke risk with no increase in intracranial or fatal hemorrhage was seen when rivaroxaban 2.5 mg twice daily was added to aspirin.
View Article and Find Full Text PDFNat Med
January 2025
Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Boston, MA, USA.
Large language models (LLMs) are rapidly being adopted in healthcare, necessitating standardized reporting guidelines. We present transparent reporting of a multivariable model for individual prognosis or diagnosis (TRIPOD)-LLM, an extension of the TRIPOD + artificial intelligence statement, addressing the unique challenges of LLMs in biomedical applications. TRIPOD-LLM provides a comprehensive checklist of 19 main items and 50 subitems, covering key aspects from title to discussion.
View Article and Find Full Text PDFPhys Rev Lett
December 2024
Institut für Kern- und Teilchenphysik, Technische Universität Dresden, Zellescher Weg 19, 01062 Dresden, Germany.
Stable ^{205}Tl ions have the lowest known energy threshold for capturing electron neutrinos (ν_{e}) of E_{ν_{e}}≥50.6 keV. The Lorandite Experiment (LOREX), proposed in the 1980s, aims at obtaining the longtime averaged solar neutrino flux by utilizing natural deposits of Tl-bearing lorandite ores.
View Article and Find Full Text PDFCirc Cardiovasc Interv
December 2024
Cardiovascular Clinical Research Center, Department of Medicine, NYU Grossman School of Medicine, New York, NY (H.R.R., L.P., S.B., J.S.H.).
Background: The relationship between the extent and severity of stress-induced ischemia and the extent and severity of anatomic coronary artery disease (CAD) in patients with obstructive CAD is multifactorial and includes the intensity of stress achieved, type of testing used, presence and extent of prior infarction, collateral blood flow, plaque characteristics, microvascular disease, coronary vasomotor tone, and genetic factors. Among chronic coronary disease participants with site-determined moderate or severe ischemia, we investigated associations between ischemia severity on stress testing and the extent of CAD on coronary computed tomography angiography.
Methods: Clinically indicated stress testing included nuclear imaging, echocardiography, cardiac magnetic resonance imaging, or nonimaging exercise tolerance test.
Circulation
December 2024
Department of Physiology and Pharmacology, Libin Cardiovascular Institute, University of Calgary, Canada (B.S., M. Ni, Y.L., Z.S., H.W., H.-L.Z., J.W., D.B., S.C., W.G., J.Y., S.T., J.P.E., R.W., S.R.W.C.).
Nat Methods
December 2024
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Over a lifetime, hematopoietic stem cells (HSCs) adjust their lineage output to support age-aligned physiology. In model organisms, stereotypic waves of hematopoiesis have been observed corresponding to defined age-biased HSC hallmarks. However, how the properties of hematopoietic stem and progenitor cells change over the human lifespan remains unclear.
View Article and Find Full Text PDFNeurology
December 2024
From the Department of Neurology (H.-P.H.), UKD, Centre of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine University Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), University of Sydney, Australia; Department of Neurology (H.-P.H.), Palacky University Olomouc, Czech Republic; Department of Neurology (R.H.B.B.), Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, NY; Department of Neurology (T.B.), Medical University of Vienna, Comprehensive Center for Clinical Neurosciences and Mental Health, Austria; Mellen Center for MS (R.A.B.), Cleveland Clinic, OH; Neurocentre Magendie INSERM (B.B.), Université de Bordeaux, France; Department of Neurology (W.M.C.), Sir Charles Gairdner Hospital, Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands; Department of Medicine and the Ottawa Hospital Research Institute (M.S.F.), University of Ottawa, Ontario, Canada; Department of Neurology (T.H.), Akershus University Hospital, Lørenskog; Institute of Clinical Medicine (T.H.), University of Oslo, Norway; Department of Neurology (R.K.), Hacettepe University Faculty of Medicine, Ankara, Turkey; Centre d'Esclerosi Mútiple de Catalunya (Cemcat) (C.N.), Vall d'Hebron Hospital Universitari, Barcelona, Spain; Department of Medical and Surgical Sciences and Advanced Technologies (F.P.), GF Ingrassia, Neuroscience Section and Multiple Sclerosis Centre, University of Catania PO Policlinico G Rodolico, Italy; Loyola University Chicago (A.P.R.), IL; Department of Neurology (L.V.), AZ Sint-Jan Brugge-Oostende, Belgium; Department of Neurology (T.V.), University of Colorado School of Medicine, Aurora; Medical Image Analysis Center (MIAC AG) (J.W.), Department of Biomedical Engineering, University of Basel; F. Hoffmann-La Roche Ltd (J.W., S.C., K.K., T.K., I.K., C.R., G.-A.T.), Basel, Switzerland; and Department of Neurology (J.K.), VU University Medical Centre, Amsterdam, the Netherlands.
Background And Objectives: Early treatment of multiple sclerosis (MS) reduces disease activity and the risk of long-term disease progression. Effectiveness of ocrelizumab is established in relapsing MS (RMS); however, data in early RMS are lacking. We evaluated the 4-year effectiveness and safety of ocrelizumab as a first-line therapy in treatment-naive patients with recently diagnosed relapsing-remitting MS (RRMS).
View Article and Find Full Text PDFERJ Open Res
November 2024
Department of Respiratory Medicine and Allergy, Tosei General Hospital, Japan.
Nat Med
December 2024
Defitech Center for Interventional Neurotherapies (.NeuroRestore), CHUV/UNIL/EPFL, Lausanne, Switzerland.
A spinal cord injury (SCI) disrupts the neuronal projections from the brain to the region of the spinal cord that produces walking, leading to various degrees of paralysis. Here, we aimed to identify brain regions that steer the recovery of walking after incomplete SCI and that could be targeted to augment this recovery. To uncover these regions, we constructed a space-time brain-wide atlas of transcriptionally active and spinal cord-projecting neurons underlying the recovery of walking after incomplete SCI.
View Article and Find Full Text PDFThromb Haemost
November 2024
Division of Hematology and Thromboembolism, Department of Medicine, Population Health Research Institute, Hamilton, Ontario, Canada.
Background: Although most patients with atrial fibrillation (AF) receiving a direct oral anticoagulant (DOAC) do not require drug concentration measurements, there are situations where such information could be useful. Existing guidance documents provide usual on-therapy ranges for drug concentrations, but these have important limitations.
Methods: This is a systematic review and meta-analysis of studies reporting trough and peak levels of DOAC regimens approved for stroke prevention in AF.
Curr Oncol
November 2024
Arthur Child Comprehensive Cancer Centre, Calgary, AB T2N 5G2, Canada.
The accurate staging of breast cancer is fundamental for guiding treatment decisions and predicting patient outcomes. However, there can be considerable variation in routine clinical practice based on individual interpretation of guidelines and depending on the healthcare provider initially involved in working up patients newly diagnosed with breast cancer, ranging from primary care providers, triage nurses, surgeons, and/or oncologists. The optimal approach for clinical staging, particularly in asymptomatic patients presenting with intermediate-risk disease, remains a topic of dialogue among clinicians.
View Article and Find Full Text PDFCurr Oncol
October 2024
Tom Baker Cancer Centre, Calgary, AB T2N 4N2, Canada.
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of breast cancer associated with a poor prognosis when sub-optimally treated. Recent advances include new and effective targeted therapies that have significantly improved outcomes for patients. Despite these advances, there are significant gaps across Canada, underscoring the need for evidence-based consensus guidance to inform treatment decisions.
View Article and Find Full Text PDFNeurology
December 2024
From the Department of Medicine and Neurology (N.Y., V.Y., L.C., B.C.V.C., H.Z., G.A.D., S.M.D.), Melbourne Brain Centre @ The Royal Melbourne Hospital, University of Melbourne; Population Health and Immunity Division (N.Y.), The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia; Division of Neurology (V.Y.), Department of Medicine, The Ottawa Hospital and Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada; Melbourne Medical School (L.C.), University of Melbourne, Parkville, Australia; Department of Neurology (A.M., D.S.), Helsinki University Hospital, Finland; Department of Neurology (T.W.), Christchurch Hospital, New Zealand; Stroke Centre and Department of Neurology (J.-S.J.), National Taiwan University Hospital, Taipei; Stroke Trials Unit (L.J.W., Z.K.L., P.M.B., N.S.), Mental Health & Clinical Neuroscience, University of Nottingham, United Kingdom; Department of Neurology (C.O.), Bispebjerg and Frederiksberg Hospital, University Hospital of Copenhagen, Denmark; Department of Medicine (Z.K.L.), Faculty of Medicine, National University of Malaysia, Kuala Lumpur; Department of Neurology (H.-Q.G., X.N., J.L., L.L.), Beijing Tiantan Hospital, Capital Medical University; China National Clinical Research Centre for Neurological Diseases (H.-Q.G., X.N., J.L., L.L.), Beijing; and Department of Neurology (H.H.M.), Monash Medical Centre, School of Clinical Sciences, Monash University, Melbourne, Australia.
Sports Med
November 2024
Department of Neuroscience, Central Clinical School, Monash University, 99 Commercial Road, Melbourne, VIC, Australia.
Background: Advances in instrumented mouthguards (iMGs) allow for accurate quantification of single high-acceleration head impacts and cumulative head acceleration exposure in collision sports. However, relationships between these measures and risk of brain cell injury remain unclear.
Aim: The purpose of this study was to quantify measures of non-concussive head impact exposure and assess their association with blood glial fibrillary acidic protein (GFAP), neurofilament light (NfL) and phosphorylated-tau-181 (p-tau-181) levels in male Australian football players.
Nature
November 2024
GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany.
Therap Adv Gastroenterol
November 2024
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Background: Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P) receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). It is known that non-serious treatment-emergent adverse events (TEAEs) may not lead to UC drug discontinuation but can affect treatment tolerability.
Objectives: This post hoc analysis evaluated the incidence of specific, common, non-serious TEAEs reported in the etrasimod UC clinical programme and the characteristics of affected patients.
Radiology
November 2024
From the Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin & Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Lindenberger Weg 80, 13125 Berlin, Germany (C.C., H.Z., A.U.B., F.P.); NeuroCure Clinical Research Ctr (C.C., H.Z., A.U.B., J.W., F.P.), Dept of Psychiatry and Neurosciences, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany (C.C.); Medical Image Analysis Center, Basel, Switzerland (V.C.e.S., E.G., D.M.); Paulista School of Medicine, Dept of Neurology and Neurosurgery (D.B.B.), Dept of Diagnostic Imaging, Universidade Federal de São Paulo, São Paulo, Brazil (M.I.I.); Koc Univ, School of Medicine Neurology Dept and Istanbul Univ, Cerrahpasa School of Medicine, Neurology Dept, Istanbul, Turkey (A.A.); Dept of Neurology, Istanbul Univ, Cerrahpasa Faculty of Medicine, Istanbul, Turkey (U.T.); Div of Neurology, Dept of Medicine, Siriraj Hosp, Mahidol Univ, Bangkok, Thailand (S.S.); Bumrungrad International Hosp, Bangkok, Thailand (S.S.); Center for Advanced Neurologic Research, KS Hegde Medical Academy, Nitte Univ, Mangalore, India (L.P., A.D.); Dept of Neurology, Hosp de S. João, Al. Hernâni Monteiro, Porto, Portugal (M.J.S., R.F.); MS Center at Swedish Neuroscience Inst, Seattle, Wash (P.Q., C.T.); Dept of Neurology and Neuroimmunology Clinic, Rabin Medical Center, Petach Tikva, Israel (I.L.); Sackler Faculty of Medicine & Felsenstein Medical Research Center, Tel Aviv Univ, Tel Aviv, Israel (I.L., H.S.K.); Dept of Radiology, Rabin Medical Center, Beilinson Hosp, Israel, and Sackler Faculty of Medicine, Tel-Aviv Univ, Tel Aviv, Israel (V.K.); Dept of Neurology and Neuroimmunology, Rabin Medical Center, Beilinson Hosp, Israel, and Sackler Faculty of Medicine, Tel-Aviv Univ, Tel Aviv, Israel (M.A.H.); Neuro-Ophthalmology Div, Dept of Ophthalmology, Rabin Medical Center, Petah Tikva, Israel (H.S.K.); Div of Neurology, Univ of Toronto, St Michael's Hosp, Toronto, Canada (D.L.R., L.W.); Mellen Center, Cleveland Clinic, Cleveland, Ohio (D.O.), Dept of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio (K.N.); Multiple Sclerosis and Neuroimmunology Program, Univ Hosps of Cleveland, Case Western Reserve Univ School of Medicine, Cleveland, Ohio (H.A., M.O.S.); Michigan Inst for Neurologic Disorders, Farmington Hills, Mich (Y.M.D.); Inst of Clinical Neuroimmunology, LMU Hosp, Ludwig-Maximillians Universität München, Munich, Germany (J.H.); Dept of Neurology, Slagelse Hosps, Odense, Denmark (N.A.); Insts of Regional Health Research & Molecular Medicine, Univ of Southern Denmark, Odense, Denmark (N.A.); Dept of Radiology, Aleris Hosp, Copenhagen, Denmark (P.B.S.); NYU Multiple Sclerosis Comprehensive Care Center, Dept of Neurology, NYU School of Medicine, New York, NY (I.K.); Dept of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine Univ Düsseldorf, Düsseldorf, Germany (M.R.); School of Medicine and Dentistry, Gold Coast Campus, Griffith Univ, Queensland, Australia (S.B., S.A.); Dept of Neurology, Gold Coast Univ Hosp, Queensland, Australia (S.A.); Dept of Pediatrics, Univ of Utah, Salt Lake City, Utah (B.M., A.M.J., M.W., S.G., L.J.C.); Dept of Medicine, Divs of Molecular Medicine & Infectious Diseases, and Ludquist Inst for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, Calif (M.R.Y.); Dept of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, Calif (M.R.Y.); Depts of Ophthalmology and Visual Sciences, Kellogg Eye Center, Univ of Michigan, Ann Arbor, Mich (T.J.S.); Div of Metabolism, Endocrine and Diabetes, Dept of Internal Medicine, Univ of Michigan Medical School, Ann Arbor, Mich (T.J.S.); Hoffmann-LaRoche, Basel, Switzerland (J.W.); Dept of Neurology, Charité-Universitätsmedizin Berlin, Germany (F.P.); Affiliated author members of the Guthy-Jackson Charitable Foundation (GJCF) International Clinical Consortium (ICC) for NMOSD are listed in Appendix S1.
J Allergy Clin Immunol
November 2024
A-T Clinical Center, Johns Hopkins Hospital, Baltimore, Md; Department of Hematology, St Jude Children's Research Hospital, Memphis, Tenn. Electronic address:
Neurology
November 2024
From the Queen Square Multiple Sclerosis Centre (G.P., F.P., J.C., B.K., O.A.-M., S.A.-A., A. Bianchi, W.J.B., R. Christensen, E.C., S. Collorone, M.A.F., Y.H., A.H., S. Mohamud, R.N., A.T.T., J.W., C.Y., O.C., F.B.), Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, United Kingdom; MS Center Amsterdam (G.P., H.V., F.B.), Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, the Netherlands; Departments of Advanced Biomedical Sciences and Electrical Engineering and Information Technology (G.P., A. Brunetti, S. Cocozza), University of Naples "Federico II," Italy; Centre for Medical Image Computing (F.P., B.K., F.B.), Department of Medical Physics and Biomedical Engineering, University College London, United Kingdom; E-Health Center (F.P.), Universitat Oberta de Catalunya, Barcelona, Spain; Institute of Neuroradiology (B.B., C.L.), St. Josef Hospital, Ruhr-University Bochum, Germany; Department of Advanced Medical and Surgical Sciences (A. Bisecco, A.G.), University of Campania "Luigi Vanvitelli," Naples, Italy; Translational Imaging in Neurology (ThINK) Basel (A.C., C. Granziera), Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel, University of Basel; Neurologic Clinic and Policlinic (A.C., C. Granziera, J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Switzerland; Department of Neurosciences, Biomedicine and Movement Sciences (M. Calabrese, M. Castellaro), University of Verona; Department of Information Engineering (M. Castellaro), University of Padova; Department of Medicine, Surgery and Neuroscience (R. Cortese, N.D.S.), University of Siena, Italy; Department of Neurology (C.E., D.P.), Medical University of Graz, Austria; Neuroimaging Research Unit (M.F., M.A.R., P.V.), Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Neurology Unit, Neurorehabilitation Unit, Neurophysiology Service, IRCCS San Raffaele Scientific Institute; Vita-Salute San Raffaele University (M.F., M.A.R., P.V.), Milan; Department of Neurosciences (C. Gasperini, S.R.), San Camillo-Forlanini Hospital, Rome, Italy; Department of Neurology (G.G.-E., S.G.), Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Germany; Department of Neurology (H.F.F.H., E.A.H., G.O.N.), Oslo University Hospital; Institute of Clinical Medicine (H.F.F.H., E.A.H., G.O.N.), and Department of Psychology (E.A.H.), University of Oslo, Norway; Neuroimmunology and Multiple Sclerosis Unit Laboratory of Advanced Imaging in Neuroimmunological Diseases (ImaginEM) (S.L., E.M.-H.), Hospital Clinic Barcelona, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Su, Barcelona, Spain; Department of Neurology (C.L.), St. Josef Hospital, Ruhr-University Bochum, Germany; Nuffield Department of Clinical Neurosciences (S. Messina, J.P.), University of Oxford, United Kingdom; Department of Molecular Medicine and Medical Biotechnology (M.M.), and Department of Neurosciences and Reproductive and Odontostomatological Sciences (M.P.), University of Naples "Federico II"; Department of Human Neurosciences (M.P.), Sapienza University of Rome, Italy; Section of Neuroradiology (A.R.), Department of Radiology, and Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (J.S.-G.), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; MS Center Amsterdam (E.M.M.S.), Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, the Netherlands; Department of Neurology and Center of Clinical Neuroscience (T.U.), and Department of Radiology (M.V.), First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; MS Center Amsterdam (M.M.S.), Anatomy and Neurosciences, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam UMC location VUmc, the Netherlands; Centre for Medical Image Computing (J.H.C.), Department of Computer Science, and Dementia Research Centre (J.H.C., F.B.), UCL Queen Square Institute of Neurology, University College London, United Kingdom.
Background And Objectives: Disentangling brain aging from disease-related neurodegeneration in patients with multiple sclerosis (PwMS) is increasingly topical. The brain-age paradigm offers a window into this problem but may miss disease-specific effects. In this study, we investigated whether a disease-specific model might complement the brain-age gap (BAG) by capturing aspects unique to MS.
View Article and Find Full Text PDFEpilepsia
January 2025
Department of Neurosciences, Pediatrics and Pharmacology, University of California San Diego School of Medicine, San Diego, California, USA.
Cholesterol is a critical molecule in the central nervous system, and imbalances in the synthesis and metabolism of brain cholesterol can result in a range of pathologies, including those related to hyperexcitability. The impact of cholesterol on disorders of epilepsy and developmental and epileptic encephalopathies is an area of growing interest. Cholesterol cannot cross the blood-brain barrier, and thus the brain synthesizes and metabolizes its own pool of cholesterol.
View Article and Find Full Text PDFNeural Netw
January 2025
Department of Mathematics, Simon Fraser University, 8888 University Drive, Burnaby BC, Canada, V5A 1S6. Electronic address:
The past decade has seen increasing interest in applying Deep Learning (DL) to Computational Science and Engineering (CSE). Driven by impressive results in applications such as computer vision, Uncertainty Quantification (UQ), genetics, simulations and image processing, DL is increasingly supplanting classical algorithms, and seems poised to revolutionize scientific computing. However, DL is not yet well-understood from the standpoint of numerical analysis.
View Article and Find Full Text PDFCurr Oncol
October 2024
William Osler Health System, Brampton, ON L6R 3J7, Canada.
The increased use of immune checkpoint inhibitors (ICIs) across cancer programs has created the need for standardized monitoring and management of immune-related adverse events (irAEs). Delayed recognition without appropriate treatment can have serious and life-threatening consequences. The management of irAEs presents a unique set of challenges that must be addressed at a multidisciplinary level.
View Article and Find Full Text PDFJ Trauma Acute Care Surg
November 2024
From the Division of Division of Trauma, Burns and Surgical Critical Care, Department of Surgery (P.D.N., J.N., N.A., A.G.), University of California, Irvine, Orange, California; Section of Surgical Sciences (J.M.S.), Vanderbilt University Medical Center, Nashville, TN; Department of Surgery, University of Colorado, Aurora, Colorado (M.C., H.C., R.M., S.U., C.C.B., C.V.); Department of Surgery (S.B., R.C.D.), UCSF-Fresno, Fresno, California; Division of Trauma and Acute Care Surgery (M.C.S.), Mount Carmel East; Trauma, Critical Care and Acute Care Surgery (A.L.), Grant Medical Center, Columbus, Ohio; Department of Surgery (M.S.F.), Lehigh Valley Health Network, Allentown, Pennsylvania; Departments of Emergency Medicine and Surgery, Program in Trauma (D.M.S.), R Adams Cowley Shock Trauma Center, University of Maryland School of Medicine, Baltimore, Maryland; Graduate Medical Education (M.S.T., H.M.G.V.), Methodist Dallas Medical Center, Dallas, Texas; Division of Trauma, Acute Care Surgery and Surgical Critical Care, Department of Surgery (C.J.M., T.J.M.), Spartanburg Regional Medical Center, Spartanburg, South Carolina; Department of Surgery (C.G.B.), University of Calgary, Calgary, Alberta, Canada; Division of Acute Care Surgery (K.M., G.M.), Loma Linda University Health, Loma Linda, California; Department of Surgery (D.J.H., H.A.), University of Maryland School of Medicine, Baltimore, Maryland; Department of Trauma and Acute Care Surgery (T.J.S., J.R.), UCHealth Memorial Hospital, Colorado Springs, Colorado; Department of General Surgery (M.B.), Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Division of Trauma, Acute Care Surgery and Surgical Critical Care (N.K., M.C.), Banner-University Medical Center Phoenix, Phoenix, Arizona; Division of Trauma and Critical Care, Department of Surgery (N.K.D., E.J.L.), Cedars-Sinai Medical Center, Los Angeles, California; Department of Surgery (T.E., J.W.), Cooper University Hospital, Camden, New Jersey; Department of Surgery and Perioperative Care (T.C.P.C., V.E.), Dell Medical School, University of Texas at Austin, Austin, Texas; Division of Trauma Acute Care Surgery, Department of Surgery (K.P., K.C.), Banner Thunderbird Medical Center, Glendale, Arizona; Division of Trauma and Surgical Critical Care, Department of Surgery (S.B.), Hackensack University Medical Center, Hackensack, New Jersey; Division of Trauma and Surgical Critical Care, Department of Surgery (F.S.E.), Rutgers New Jersey Medical School, Newark, New Jersey; Department of Trauma and Acute Care Surgery (W.D., C.P.), Medical Center of the Rockies, Loveland, Colorado; University of Wisconsin-Madison School of Medicine and Public Health (N.L.W.), Madison, Wisconsin; Department of Trauma (J.M.H., K.L.), Ascension Via Christi Saint Francis, Wichita, Kansas; Department of Surgery (G.S.), Miami Valley Hospital, Wright State University, Dayton, Ohio; Department of Surgery (K.S.), Prisma Health-Upstate, Greenville, South Carolina; and Department of Surgery (L.A.H.), Boulder Community Hospital, Boulder, Colorado.
Background: Prior studies evaluating observation versus angioembolization (AE) for blunt liver injuries (BLT) with contrast extravasation (CE) on computed tomography imaging have yielded inconsistent conclusions, primarily due to limitations in single-center and/or retrospective study design. Therefore, this multicenter study aims to compare an observation versus AE-first approach for BLT, hypothesizing decreased liver-related complications (LRCs) with observation.
Methods: We conducted a post hoc analysis of a multicenter, prospective observational study (2019-2021) across 23 centers.